How to read the result
| Criteria set | What has to be true |
|---|
| EOLIA (any one; ventilated under 7 days) | P/F below 50 mmHg for over 3 hours, or below 80 mmHg for over 6 hours, on FiO2 0.8 or more with tidal volume set at 6 mL/kg and a trial of PEEP 10 cmH2O or more. Or pH below 7.25 with PaCO2 60 mmHg or more for over 6 hours, with the rate raised to 35/min and plateau pressure kept at 32 cmH2O or less. |
| ELSO 2021 (any one) | P/F below 80 mmHg after optimal care, including a prone trial unless contraindicated; pH below 7.25 with PaCO2 60 mmHg or more despite optimal ventilation (rate 35/min, plateau 30 cmH2O or less); bridge to lung transplant or primary graft dysfunction. |
“Met” means the criteria for considering VV-ECMO are present, not that cannulation should follow; ELSO states its guidance does not replace medical judgment and the multidisciplinary decision on ECMO.
Criteria
P/F = PaO2 (mmHg) ÷ FiO2 (as a fraction)
PaO2 in kPa × 7.5 gives mmHg. For the hypercapnic criterion EOLIA lowered tidal volume in 1 mL/kg steps to 4 mL/kg, then PEEP to no less than 8 cmH2O, to keep plateau pressure at 32 cmH2O or less. EOLIA also excluded, among others, pregnancy, BMI above 45, chronic respiratory failure on long-term oxygen or ventilation, cardiac failure needing VA-ECMO, prior heparin-induced thrombocytopenia and a SAPS II above 90.
Before ECMO, ELSO asks for evidence-based ARDS care: low tidal volume ventilation (4-6 mL/kg PBW) and prone positioning unless contraindicated, with no delay once ECMO is indicated. ESICM 2023 recommends prone positioning for moderate to severe ARDS (P/F below 150 mmHg) and recommends against routine continuous infusions of neuromuscular blockers. ELSO’s only absolute contraindication is expected non-recovery without a plan for decannulation; its relative contraindications are central nervous system hemorrhage, significant or irreversible incapacitating CNS injury or disease, systemic bleeding, contraindication to anticoagulation, immunosuppression, older age (no cut-off set) and ventilation for over 7 days with plateau pressure above 30 cmH2O and FiO2 above 90%.
Evidence
In EOLIA, 249 patients with very severe ARDS were randomized to immediate VV-ECMO or conventional care with rescue ECMO; 60-day mortality was 35% against 46% (relative risk 0.76, P=0.09), and 28% of controls crossed over to ECMO. CESAR found better survival without severe disability after referral to an ECMO center (63% against 47%). Pooling both trials, the ESICM 2023 guideline found lower 60-day mortality with VV-ECMO (RR 0.72) and strongly recommends ECMO for severe ARDS meeting EOLIA criteria, in an ECMO center that meets defined organizational standards, with management like EOLIA’s.
References
- Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965-1975. PMID 29791822
- Extracorporeal membrane oxygenation (ECMO) for severe acute respiratory distress syndrome (ARDS) (EOLIA): eligibility criteria. ClinicalTrials.gov. NCT01470703
- Tonna JE, Abrams D, Brodie D, et al. Management of adult patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO): guideline from the Extracorporeal Life Support Organization (ELSO). ASAIO J. 2021;67(6):601-610. PMID 33965970
- Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023;49(7):727-759. PMID 37326646
- Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351-1363. PMID 19762075